Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice hold bud! INHX is looking real strong. CONGRATS!!!
INHX am still Long>>GOOOO Baby Gooooooo
The momo continues. Will be $15 next week. Tomorrow will break the $12 resistance.
Last Two Weeks have been Absolutely Insane!
INHX Nice day here indeed
INHX (10.70) with 11.98 HOD>>>>>>>>> Hep C is in PLAYYYYYYY
What's Next for Hep C Drug Stocks Following Gilead's $11B Pharmasset Buy?
By Adam Feuerstein 11/21/11 - 11:40 AM EST
BOSTON (TheStreet) -- Semi-random thoughts and questions about hepatitis C drug stocks in the wake of Gilead Sciences(GILD) buying Pharmasset(VRUS) for $11 billion:
More from Adam Feuerstein
*
Gilead Pays $11 Billion for Pharmasset
Wow, $11 billion is a lot of money, but that's what happens when you dangle a great hepatitis C drug (Pharmasset's PSI-7977) in front of a desperate buyer (Gilead.)
One of the best bio-pharma acquisitions measured by return on investment (ROI) was Gilead's $464 million purchase of Triangle Pharmaceuticals in 2003. The Triangle deal gave Gilead the HIV drug Emtriva, which when combined with Gilead's HIV drug Viread into a single pill, created Truvada. In turn, Gilead has generated tens of billions of dollars in sales from Truvada and various HIV regimens that incorporate Truvada as a backbone.
Gilead's challenge will be to convince investors that it can deliver a decent ROI with Pharmasset by spending $11 billion to acquire the asset.
One hedge fund shareholder isn't buying it. "They're dead to me," he said, in a phone call, spitting mad. With Gilead shares down 11% to $35.23, this hedge funder doesn’t appear to be a lone voice of dissent. [See below for more buy-side investor reactions.]
Inhibitex(INHX) is up Monday. Achillion Pharmaceuticals(ACHN) shares are higher too, although less so. Both companies are developing their own hepatitis C drugs and neither company has a partner yet, so no surprise that already-present speculation about M&A activity involving these two stocks is ramping even higher.
The Inhibitex buzz makes some sense because its drug belongs to the same class of nucleotide polymerase inhibitors -- "nucs" for short -- that Pharmasset is developing.
Meantime, Achillion's CEO can't seem to pass a reporter's microphone without reminding everyone that he's in "advanced talks" with potential partners or aquirers. Smart, effective bio-pharma CEOs get deals done, they don't talk about them incessantly.
Idenix Pharmaceuticals(IDIX) shares are also up Monday on the same M&A speculation, although the stock should probably be selling off. A large part of the bull thesis on Idenix has been based on speculation that the company's intellectual property (IP) portfolio around Hep C "nucs" would allow it to demand and receive royalty payments from other companies developing similar drugs, most notably Pharmasset.
McNicoll Lewis & Vlak Reiterates Buy rating on Inhibitex Following Positive Study Data
MLV & Co has reiterated their BUY rating and raised their price target on Inhibitex, Inc, (NASDAQ: INHX) on positive study data for INX-189, and better-than-estimates earnings.
In their report, MLV writes, "INHX announced top-line data studying the safety, efficacy, and tolerability of INX-189 from the first cohort of patients, dosed at 200 mg/day as monotherapy. Impressively, 200mg INX-189 given for seven days led to a -4.25log reduction of HCV RNA. While the study is still ongoing, these data are amongst the strongest observed for a nucleotide inhibitor to date." Further more, MLV saw Inhibitex Inc beat earnings estimates on greater cost efficiencies: "INHX reported 3Q:11 Net Loss of ($5.3M) and EPS of ($0.07), compared to the Street Consensus Estimates of ($6.7M) and EPS of ($0.09), and our estimates of ($5.7M) and EPS of ($0.08)."
As of close of trading on Friday, INHX was up 115.66% to $8.54 per share.
When it comes to investing, you cannot settle for anything less than the fastest and most efficient news feed. That is why we created Benzinga Pro. Sign up for a free trial today!
INXH +10.18% 9.49 x 9.50 already breached $.10>>>>>>>
INHX $10 PREMARKET!!! Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
INHX $8.59: Inhibitex shares double on positive study data
Inhibitex shares double after positive results from mid-stage hepatitis C drug study
ap
Related Quotes
Symbol Price Change
INHX 8.54 +4.58
Chart for Inhibitex, Inc.
PFE 19.66 -0.22
On Friday November 4, 2011, 11:27 am EDT
ALPHARETTA, Ga. (AP) -- Shares of Inhibitex Inc. doubled in price Friday, after the drug developer said early data from a mid-stage study showed that a 200-milligram dose of its potential hepatitis C treatment did well in reducing the virus in patients.
Inhibitex said the dose of the drug, labeled INX-189, was well tolerated, with no serious side effects, when given to patients with a certain form of chronic hepatitis who have not been treated. The drug was administered for seven days.
Shares of the Alpharetta, Ga., company climbed $4.04 to $8 in late morning trading Friday.
Analysts have called INX-189 a promising treatment for Hepatitis C, a disease that is expected to become a larger public health problem as baby boomers get older. Hepatitis C is the primary cause of liver transplants in the U.S.
Hepatitis C is spread through the blood, including by sharing needles or having sex with an infected person. The disease could also be picked up from blood transfusions before 1992, when testing of the blood supply for the virus began.
Most people with hepatitis C don't even know they have the virus until after liver damage has occurred, which can cause abdominal pain, fatigue, itching and dark urine.
Inhibitex focuses on developing treatments for viral infections and does not have any products on the market. The company also said Friday that it lost $5.3 million, or 7 cents per share, in the three months that ended Sept. 30. It also recorded a $5.3 million loss last year, when Inhibitex had fewer shares on the market and the loss equated to 8 cents per share.
Revenue jumped to $1.3 million from $300,000 due to a $1 million milestone payment from New York-based Pfizer Inc.
this one could even move to over 10$ today.
price targets will be raised to over 14$
INHX about to compete with VRUS (Pharmasset), who with PSI-7977 went from $10 to over $70 per share over the past 24 months and that included a 2:1 split this past September.
surf1944 you have been telling everyone since June about INHX, and you sure nailed it! Enjoy your next 3-5 years!
It should be the "new gold" for investors for the next 18 months until trial updates are released.
Crazy move here so far today..... Looks like it ain't done either
Inhibitex Soars as Investors See Another Pharmasset in the Making
http://www.thestreet.com/_yahoo/story/11300434/1/inhibitex-soars-as-investors-see-another-pharmasset-in-the-making.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
7:25AM Inhibitex beats by $0.01; provides new topline data on clinical trial of INX-189 (INHX) 3.96 : reports Q3 EPS of ($0.07) vs ($0.08) Cap IQ consensus; revs increased by $1 mln to $1.3 mln vs $0.7 mln consensus. As of September 30, 2011, the Company held $53.7 mln in cash, cash equivalents, short-term and long-term investments. The co also reported top-line safety and antiviral data from the first cohort of its ongoing clinical trial of INX-189. In this study, 200 mg INX-189, dosed once-daily for seven days, continued to demonstrate potent and dose-dependent antiviral activity with a median HCV RNA reduction from baseline of -4.25 log10 IU/mL. Further, 200 mg INX-189 was generally well tolerated, and there were no serious adverse events or dose dependent adverse events observed. The co also reported today that it has initiated a Phase 1 drug/drug interaction study in healthy volunteers of INX-189 and an HCV direct acting antiviral compound.
Hepatitis C Drug Developers See Shares Rise After News Of Roche Acquisition
http://seekingalpha.com/article/300575-hepatitis-c-drug-developers-see-shares-rise-after-news-of-roche-acquisition?source=yahoo
7:16AM On The Wires (WIRES)
Inhibitex (INHX) announced that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naive patients.
Inhibitex to Present at Two Upcoming Conferences
Press Release Source: Inhibitex, Inc. On Thursday August 25, 2011, 4:32 pm EDT
ATLANTA--(BUSINESS WIRE)-- Inhibitex, Inc. (NASDAQ:INHX - News), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, announced that executive management is scheduled to present an overview of the company and its pipeline at the following two conferences:
-- Joseph M. Patti, senior vice president of research and development and chief scientific officer, will present at the Stifel Nicolaus Healthcare Conference, on Wednesday, September 7, 2011 at 2:40 pm EDT. The conference is being held at The Four Seasons Hotel in Boston, Massachusetts.
-- Russell H. Plumb, president and chief executive officer, will present at the JMP Securities Fifth Annul Healthcare Conference, on Wednesday, September 28, 2011 at 8:30 am EDT. The conference is being held at The St. Regis New York Hotel in New York, New York.
The presentations will be simultaneously webcast and can be accessed by visiting the Investors section of the Inhibitex website at www.inhibitex.com. Shortly following the live webcast a replay will also be available on the Company website.
http://finance.yahoo.com/news/Inhibitex-to-Present-at-Two-bw-2477696672.html?x=0&.v=1
Buying Into a Hot Hepatitis C Drug Market
Inhibitex’s hepatitis C drug, INX-189, is being studied in the second of three phases of human trials generally needed for FDA approval. The treatment is part of a drug class known as nucleotide polymerase inhibitors. Public since 2004, the company also is studying a treatment for shingles, but Russo calls INX-189 “the real value driver.” He also says he believes Inhibitex will seek a partner to help develop the hepatitis drug.
http://www.minyanville.com/businessmarkets/articles/hepatitis-c-pharmasset-vertex-merck-johnson/8/25/2011/id/36565?camp=syndication&medium=portals&from=yahoo
Ahead of the Bell: Inhibitex rates 'outperform'
Baird analyst starts Inhibitex coverage with 'outperform' rating
The Associated Press, On Thursday August 25, 2011, 9:23 am EDT
Inhibitex has a promising potential treatment for the Hepatitis C virus, according to a Baird analyst who started coverage of the biotechnology company with an "outperform" rating.
Thomas J. Russo said in a Thursday morning research note the Alpharetta, Ga., company's molecule labeled INX-189 is a "real value driver" in an important class of treatments. INX-189 is a potential Hepatitis C treatment called a nucleotide polymerase inhibitor in mid-stage drug development. The analyst said these drugs have a "scarcity value" and that compound appears "very much in the game."
Inhibitex Inc. does not have any products on the market, and most of its revenue comes from collaborations. It focuses on developing treatments for viral infections, and it also has a potential shingles treatment in late-stage testing.
Hepatitis C is the primary cause of liver transplants in the U.S. and is expected to become a much larger public health problem as aging baby boomers succumb to the disease.
Hepatitis C is an infectious disease that is spread through the blood, including by sharing needles or having sex with an infected person. The disease could also be picked up from blood transfusions before 1992, when testing of the blood supply for the virus began.
Most people with hepatitis C don't even know they have the virus until after liver damage has occurred, which can cause abdominal pain, fatigue, itching and dark urine.
Inhibitex announces staphylococcus aureus investigational vaccine elicits a positive immune response in phase 1 study (INHX) 3.62 : Co announced that Pfizer (PFE) presented safety and immunogenicity data from a Phase 1 double-blind randomized placebo controlled study in 408 healthy volunteers of a novel three antigen Staphylococcus aureus investigational vaccine at the 21st European Congress of Clinical Microbiology and Infectious Diseases and International Congress of Chemotherapy. The vaccine candidate is comprised of S. aureus capsular polysaccharide serotypes 5 and 8 conjugated to CRM197 and the recombinant surface-expressed MSCRAMM protein, clumping factor A. In the Phase 1 study, the vaccine elicited a positive immune response to each of the three components. Pfizer has worldwide exclusive rights to the Company's MSCRAMM protein platform for the development of staphylococcal vaccines.
FV-100? I've always discounted this one because there are dozens of co.'s working on this, yet the last PR was promising. I think Ph. II was completed in Nov.(?) The trial lasted 6mos.
The “news” you’re speaking of was the data release from EASL: #msg-61668669. This release was not really newsworthy insofar as INHX issued a similar PR in January, but some investors apparently didn’t know that.
One caveat here, occasionally these offerings go hand in hand with news, for obvious reasons. I haven't been here as long as Ron, but since sub-dollar and, IMO, this company's finances have been run so much better than most small bio-techs. No paid PR or b.s. "news" releases. Every dip has retraced soon after, and then some. Very few seem to time offerings with milestones. I never understood why. I'm not expecting it, but I wouldn't be too surprised. There seems to be some smart-money involved w/this co.
I agree INHX is an amazing stock, but the PPS does not hold. This time because of the prospectus, I know from the roller coaster ride.
Just look at the cost in the years. I'm still going to buy when it dips and I take my 20K loss from penny land and ihub..
Lesson learned. INHX alwasy did me right.. just watch the dips.. they can hurt..
6/4/2004 BUY ORDER POSTING INHX 300.0000 -$2,225.55
11/13/2008 BUY ORDER POSTING INHX 1000.0000 -$214.95
12/11/2009 BUY ORDER POSTING INHX 1000.0000 -$799.92
5/12/2010 SELL ORDER POSTING INHX -652.8205 $1,803.85
4/8/2010 SELL ORDER POSTING INHX -1000.0000 $1,590.05
4/8/2010 SELL ORDER POSTING INHX -1000.0000 $1,590.05
4/8/2010 SELL ORDER POSTING INHX -1000.0000 $1,570.05
INHX’s HCV data presented at EASL was no big deal. You may find this survey of interest: #msg-61754242. Regards, Dew
Having been in this since IPO its very hard for INHX to hold its gains.. I doubt you will see $2.00 again but $3's are very near, at that point I will start buying back in. Once INHX can break $5 and stay there for a week, more institutional investors will be back. But for now with the prospectus I see this dropping back to mid $3's.. Could be wrong but till they produce rev's its not going to far up. -IMO
Watch it closely
Both OPTR and INHX in positive view: Both FDA plays.. INHX target price $7
* March 31, 2011, 3:51 PM ET
Canaccord Bullish on OPTR, INHX
By Teresa Rivas
Canaccord Genuity analyst George Farmer today reiterated his Buy ratings on both Inhibitex (INHX) and Optimer Pharmaceuticals (OPTR), on positive data and an upcoming FDA meeting, respectively.
For Inhibitrex, Farmer raised his target price from $5 to $7, on the release of positive seven-day dosing data from a Phase Ib trial evaluating INX-189 for treatment of hepatitis C virus infection.
“Though early, we think these data further strengthen the value proposition of INX-189 and support further evaluation in longer-term combination HCV trials,” he wrote in a research note. “Clinical-stage nucs like INX-189 will likely form the backbone of future HCV therapy, in our view, and scarcity could make INX-189 a highly coveted asset once longer-term safety trials are complete.”
Farmer is also bullish on Optimer Pharmaceuticals ahead of an FDA advisory committee meeting next week, as he anticipates it will support the company’s lead drug, fidaxomicin, for treatment of C. diff. infection, the most common cause for antimicrobial, drug-associated diarrhea in the U.S.
“Initially to be positioned in a ‘high-risk’ treatment market and in vancomycin failures, we model for a slow ramp to peak fidaxomicin sales of $250 million by 2016,” he wrote.
http://blogs.barrons.com/stockstowatchtoday/2011/03/31/canaccord-likes-optr-inhx/?mod=yahoobarrons
INHX looking solid for a multi-day run imo
Composite Indicators Signal
TrendSpotter Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Buy
Short Term Indicators Average: 100% Buy
20-Day Average Volume - 689,837
Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 100% Buy
50-Day Average Volume - 431,185
Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 100% Buy
100-Day Average Volume - 471,671
Overall Average: 100% Buy
NEWS
BOSTON (MarketWatch) -- Shares of Inhibitex Inc. rocketed 2% to $4.52 Friday
afternoon. On Thursday, the biotech group reported positive safety data from a
Phase I clinical trial for INX-189 in the treatment of chronic infections caused
by hepatitis C.
Good to see you over here Ron...INHX consolidating nicely on the 3-min chart. Looking for an after lunch run to test HOD. I can't believe you had this in the penny's! GLTY.
Can I cry now.. I had this at IPO and averaged down when it was .28 sold it all @ $2.75
DAMN!!!!!!! I wanted to get back in, playing high risk penny stocks and lost my butt. Missed my baby INHX.. !!!
Inhibitex - could be breaking out of a bullish ascending triangle formation, and volume is picking up also. Chart looks promising -
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=inhx&insttype=&freq=1&show=&time=9
Hey, Hey OC:
Agreed, with one or two caveats.
I wouldn't discount the importance of a once-a-day regimen. A greater % of potential patients are going to be elderly. In digging through some coffee-stained notes, I found a reference to an old press release touting the importance of this going into trial. Reducing dosage frequency is a valuable tool/goal in elder care (a growing mkt.) and there are plenty of precedent examples. Also the metric allows for profit in bringing a drug to mkt. that has similar efficacy (there are always individual differences/preferences). Esp. if it uses a different pathway(?).
Your succinct list of "squawks" as a general reaction brought a chuckle. It was spot-on.
Hi skitstovel,
Once a day dosing (QD dosing) is a favorable aspect of FV-100 but don't lose sight of the the fact this drug failed to meet it's primary and secondary endpoints which is the key metric in biotech development. The resulting complaints, from questionable sources, are always the same:
*the study wasn't designed right
*they will use a higher dose
*increase the time duration and the efficacy will improve
The bottom line with this trial is FV-100 needed to show an improvement of at least %20 over generic Valacyclovir for any company to consider partnering this drug. Inhibitex knew it when the trial began, the industry knew it, and hedge funds knew it. Now that results are in isn't it amusing how the story changes?
In contrasting FV-100 with valacyclovir, why wouldn't a once-a-day dosage become the preferred treatment? Perhaps I'm just naive, but it seems this is a no-brainer.
Also, given the high widespread occurrence of "HZ" virus, and the possibility of incidental differences in efficacy (or even the prospect of "piggybacking") it seems that there is easy potential for this drug to be very profitable. No?
Bullish article on INHX and my response to it.
http://seekingalpha.com/instablog/282594-jason-napodano/120721-thoughts-on-inhibitex-fv-100-phase-2-data
Well researched article though I disagree with the conclusions. The fact that you pointed out FV-100 would be competing against generic valacyclovir was an honest disclosure and the #2 reason Inhibitex's drug won't find a partner. The first being they failed to meet both their primary and secondary endpoints.
Question:
"Will management test a higher dose of FV-100 or a longer duration? "
Answer:
No. During the C.C. the question was asked about pushing the dosage. They said safety studies were done at 800mg and then radio silence.[Sometimes what's not said is as important as what's volunteered] As for longer duration another trial and a partner would be needed which isn't in the cards IMO.
"Management has additional safety data of FV-100 800mg QD as well."
Where is it? All I see is a trending higher SAE rates at the 400mg dose.
Please let me know if you get the data on the 800mg safety study and I may change my mind.
No worries, I've been watching then for almost three yrs. This co. produces no PR and very little news, all I know is from the pdf's they provide on their website (keep an open window on Wiki to get through them). I did that research way back when and haven't revisited it since as the stock has done little but steadily go up since the end of '08. Today's plunge will be unprecedented in my experience as a stockholder.
To be honest, I dont know much about them. I saw the drop in price on what I at first took as good news and I figured the gap (2.40) would be good for a support bounce, sorry I cant answer your question.
Wasn't their goal to reduce the dosage to a once-a-day oral administration? Or am I missing something? Increased efficacy would be a plus and only hinted in the previous trials. But, to my knowledge, not the main intent.
Followers
|
7
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
219
|
Created
|
11/15/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |